Press Releases

Date Title
5 Sep 2023 Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
28 Aug 2023 Illumina To Webcast Upcoming Investor Conference
17 Aug 2023 Illumina expands genomics capabilities in India with opening of Solutions Center
11 Aug 2023 Illumina To Webcast Upcoming Investor Conference
9 Aug 2023 Dr. Steven Barnard Appointed Chief Technology Officer
9 Aug 2023 Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023
25 Jul 2023 Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
18 Jul 2023 Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
18 Jul 2023 The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
11 Jul 2023 Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery
11 Jun 2023 Illumina announces CEO transition plan
5 Jun 2023 Illumina releases 2022 Corporate Social Responsibility Report
2 Jun 2023 Illumina's Board of Directors elects two experienced Independent Directors to Board
1 Jun 2023 Illumina unveils AI software to predict disease-causing genetic mutations in patients
31 May 2023 Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023
30 May 2023 Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
25 May 2023 Illumina announces preliminary results of annual meeting
18 May 2023 Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees
16 May 2023 Illumina's genomic technologies enable better pathogen preparedness and response
15 May 2023 Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience
12 May 2023 Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees
8 May 2023 Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan"
2 May 2023 Illumina increases equitable access to STEM education, reaching over 1 million learners
1 May 2023 Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card
25 Apr 2023 Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth
20 Apr 2023 Illumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees
12 Apr 2023 Illumina's cloud-based informatics programs recognized for robust, international data privacy protections
11 Apr 2023 Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients
5 Apr 2023 Illumina celebrates 25 years of innovation
4 Apr 2023 Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023
4 Apr 2023 Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023
3 Apr 2023 Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024
30 Mar 2023 Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee
27 Mar 2023 Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease
24 Mar 2023 Illumina Issues Statement in Response to Carl Icahn's Letter
20 Mar 2023 Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements
14 Mar 2023 Illumina launches its first product enabling long- and short-read sequencing on one instrument
13 Mar 2023 Illumina Responds to Icahn Partners' Nomination of Directors
2 Mar 2023 Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
27 Feb 2023 Illumina To Webcast Upcoming Investor Conference
8 Feb 2023 Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute
7 Feb 2023 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022
1 Feb 2023 Illumina Appoints Joydeep Goswami Chief Financial Officer
10 Jan 2023 Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
9 Jan 2023 Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen